OPDYTA 40MG

Description
Nivolumab is a generic form of brand name Opdyta 40mg which is a targeted therapy drug presently used to cure melanoma, non-small cell lung cancer or kidney (renal cell) cancer. Opdyta 40mg belongs to a group of cancer drugs known as monoclonal antibodies. 
Opdyta 40mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

Indication
Opdyta 40mg is indicated for the treatment of patients having conditions like :
•    Melanoma which has spread or can’t be removed with surgery 
•    Non-Small Cell Lung Cancer which has spread or come back after chemotherapy
•    Kidney (Renal Cell) Cancer which has come back after chemotherapy.

Mechanism Of Action
Opdyta stops the molecule activity called PD-1, and it is a protein which inhibits T cells from identifying and attacking inflamed tissues and cancer cells. PD-1 can trick the immune system into overlooking melanoma cells as normal cells. Opdyta triggers your immune system’s reacting to melanoma by inhibiting the PD-1 protein on T cells. The drug activates T cells to which they can attack melanoma cells anywhere in your body.

Dosage  
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity 
With ipilimumab. The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment 

Side Effects

Common side effects :
Fatigue, Lymphocytopenia (Low White Blood Cells), Low Sodium, Shortness of breath, Musculoskeletal Pain, Decreased Appetite, Cough.

Less common side effects :
Constipation, Increased serum creatinine, Colitis, Low potassium, Low magnesium, High calcium, Vomiting, Weakness, Diarrhea, High potassium, Low calcium, Swelling, Fever, Rash, Abdominal pain, Increased serum AST, Thrombocytopenia, Increased serum alkaline phosphatase, Chest pain, Weight loss, Drug interaction, No formal pharmacokinetic drug interaction studies.

Pregnancy
The effects of Opdyta 40mg are expected to be greater during the second and third trimesters of pregnancy. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

Storage
Store at under refrigeration at 2°C to 8°C.

Missed Dose
If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

FOR MORE INFORMATION:

EMAIL:
applepharmaceutical@gmail.com

PHONE:
+91- 9987711567

VISIT US:
anti-cancer-drugs.com/opdyta-40mg.php